Two year follow-up of Crohn's patients substituted to certolizumab anti-TNFa therapy: SAVANT 2

Andrew Motlis, Moheb Boktor, Paul Jordan, Urska Cvek, Marjan Trutschl, J. Steven Alexander

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The effectiveness of ant-TNF ‘biologic’ therapy in is well supported in the management of moderate to severe Crohn's Disease (CD). Our first ‘SAVANT’ study was to our knowledge the first study report one- year outcomes in patients (n = 60) who switched from previous anti-TNFa treatment to Cimzia/Certolizumab. This current study (SAVANT 2) follows up on longer term outcomes and provides additional clinical and biochemical data that may contribute to therapeutic responses. This IRB approved study was a retrospective analysis of the initial patients included in SAVANT 1. Patients who were switched to TNF antagonist Certolizumab as an alternative biologic were followed an additional year. Retrospective consideration of immunomodulator use, smoking status and clinical data were also evaluated. Of 60 patients with moderate-severe CD who participated in the SAVANT 1 study, 15 patients were excluded due to inadequate follow up. 45 patients were studied for a total of two years following substitution with Certolizumab from prior anti TNF agent therapy. Clinical remission at 1 year was 75% (45/60) and 55% (25/45) at the second year. At the second year, 5 more patients had discontinued Certolizumab due to worse disease or adverse events, indicating a cumulative two-year failure rate of 33% (20/60). Smoking and concomitant use of immunomodulators were similar between ‘success’ and ‘failure’ groups. SAVANT 2, the first study to report long term outcomes of switching from Infliximab or Adalimumab to Certolizumab showed that at 2 years, 25 patient's maintained clinical remission. The discontinuation rates were 25 and 11% at years 1 & 2 respectively. The 5 patients who lost responsiveness after the first year were women, the majority of smoked. Additional prospective studies to assess the appropriateness and feasibility of biologic substitution are still needed.

Original languageEnglish (US)
Pages (from-to)291-295
Number of pages5
JournalPathophysiology
Volume24
Issue number4
DOIs
StatePublished - Dec 2017
Externally publishedYes

Fingerprint

Therapeutics
Immunologic Factors
Crohn Disease
Smoking
Biological Therapy
Ants
Research Ethics Committees
Prospective Studies
Adalimumab
Certolizumab Pegol
Infliximab

Keywords

  • Biologic therapy
  • Certolizumab
  • Crohn's Disease

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Physiology (medical)

Cite this

Two year follow-up of Crohn's patients substituted to certolizumab anti-TNFa therapy : SAVANT 2. / Motlis, Andrew; Boktor, Moheb; Jordan, Paul; Cvek, Urska; Trutschl, Marjan; Alexander, J. Steven.

In: Pathophysiology, Vol. 24, No. 4, 12.2017, p. 291-295.

Research output: Contribution to journalArticle

Motlis, Andrew ; Boktor, Moheb ; Jordan, Paul ; Cvek, Urska ; Trutschl, Marjan ; Alexander, J. Steven. / Two year follow-up of Crohn's patients substituted to certolizumab anti-TNFa therapy : SAVANT 2. In: Pathophysiology. 2017 ; Vol. 24, No. 4. pp. 291-295.
@article{47b1e77f042c4145982fdcef872347f0,
title = "Two year follow-up of Crohn's patients substituted to certolizumab anti-TNFa therapy: SAVANT 2",
abstract = "The effectiveness of ant-TNF ‘biologic’ therapy in is well supported in the management of moderate to severe Crohn's Disease (CD). Our first ‘SAVANT’ study was to our knowledge the first study report one- year outcomes in patients (n = 60) who switched from previous anti-TNFa treatment to Cimzia/Certolizumab. This current study (SAVANT 2) follows up on longer term outcomes and provides additional clinical and biochemical data that may contribute to therapeutic responses. This IRB approved study was a retrospective analysis of the initial patients included in SAVANT 1. Patients who were switched to TNF antagonist Certolizumab as an alternative biologic were followed an additional year. Retrospective consideration of immunomodulator use, smoking status and clinical data were also evaluated. Of 60 patients with moderate-severe CD who participated in the SAVANT 1 study, 15 patients were excluded due to inadequate follow up. 45 patients were studied for a total of two years following substitution with Certolizumab from prior anti TNF agent therapy. Clinical remission at 1 year was 75{\%} (45/60) and 55{\%} (25/45) at the second year. At the second year, 5 more patients had discontinued Certolizumab due to worse disease or adverse events, indicating a cumulative two-year failure rate of 33{\%} (20/60). Smoking and concomitant use of immunomodulators were similar between ‘success’ and ‘failure’ groups. SAVANT 2, the first study to report long term outcomes of switching from Infliximab or Adalimumab to Certolizumab showed that at 2 years, 25 patient's maintained clinical remission. The discontinuation rates were 25 and 11{\%} at years 1 & 2 respectively. The 5 patients who lost responsiveness after the first year were women, the majority of smoked. Additional prospective studies to assess the appropriateness and feasibility of biologic substitution are still needed.",
keywords = "Biologic therapy, Certolizumab, Crohn's Disease",
author = "Andrew Motlis and Moheb Boktor and Paul Jordan and Urska Cvek and Marjan Trutschl and Alexander, {J. Steven}",
year = "2017",
month = "12",
doi = "10.1016/j.pathophys.2017.07.004",
language = "English (US)",
volume = "24",
pages = "291--295",
journal = "Pathophysiology",
issn = "0928-4680",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Two year follow-up of Crohn's patients substituted to certolizumab anti-TNFa therapy

T2 - SAVANT 2

AU - Motlis, Andrew

AU - Boktor, Moheb

AU - Jordan, Paul

AU - Cvek, Urska

AU - Trutschl, Marjan

AU - Alexander, J. Steven

PY - 2017/12

Y1 - 2017/12

N2 - The effectiveness of ant-TNF ‘biologic’ therapy in is well supported in the management of moderate to severe Crohn's Disease (CD). Our first ‘SAVANT’ study was to our knowledge the first study report one- year outcomes in patients (n = 60) who switched from previous anti-TNFa treatment to Cimzia/Certolizumab. This current study (SAVANT 2) follows up on longer term outcomes and provides additional clinical and biochemical data that may contribute to therapeutic responses. This IRB approved study was a retrospective analysis of the initial patients included in SAVANT 1. Patients who were switched to TNF antagonist Certolizumab as an alternative biologic were followed an additional year. Retrospective consideration of immunomodulator use, smoking status and clinical data were also evaluated. Of 60 patients with moderate-severe CD who participated in the SAVANT 1 study, 15 patients were excluded due to inadequate follow up. 45 patients were studied for a total of two years following substitution with Certolizumab from prior anti TNF agent therapy. Clinical remission at 1 year was 75% (45/60) and 55% (25/45) at the second year. At the second year, 5 more patients had discontinued Certolizumab due to worse disease or adverse events, indicating a cumulative two-year failure rate of 33% (20/60). Smoking and concomitant use of immunomodulators were similar between ‘success’ and ‘failure’ groups. SAVANT 2, the first study to report long term outcomes of switching from Infliximab or Adalimumab to Certolizumab showed that at 2 years, 25 patient's maintained clinical remission. The discontinuation rates were 25 and 11% at years 1 & 2 respectively. The 5 patients who lost responsiveness after the first year were women, the majority of smoked. Additional prospective studies to assess the appropriateness and feasibility of biologic substitution are still needed.

AB - The effectiveness of ant-TNF ‘biologic’ therapy in is well supported in the management of moderate to severe Crohn's Disease (CD). Our first ‘SAVANT’ study was to our knowledge the first study report one- year outcomes in patients (n = 60) who switched from previous anti-TNFa treatment to Cimzia/Certolizumab. This current study (SAVANT 2) follows up on longer term outcomes and provides additional clinical and biochemical data that may contribute to therapeutic responses. This IRB approved study was a retrospective analysis of the initial patients included in SAVANT 1. Patients who were switched to TNF antagonist Certolizumab as an alternative biologic were followed an additional year. Retrospective consideration of immunomodulator use, smoking status and clinical data were also evaluated. Of 60 patients with moderate-severe CD who participated in the SAVANT 1 study, 15 patients were excluded due to inadequate follow up. 45 patients were studied for a total of two years following substitution with Certolizumab from prior anti TNF agent therapy. Clinical remission at 1 year was 75% (45/60) and 55% (25/45) at the second year. At the second year, 5 more patients had discontinued Certolizumab due to worse disease or adverse events, indicating a cumulative two-year failure rate of 33% (20/60). Smoking and concomitant use of immunomodulators were similar between ‘success’ and ‘failure’ groups. SAVANT 2, the first study to report long term outcomes of switching from Infliximab or Adalimumab to Certolizumab showed that at 2 years, 25 patient's maintained clinical remission. The discontinuation rates were 25 and 11% at years 1 & 2 respectively. The 5 patients who lost responsiveness after the first year were women, the majority of smoked. Additional prospective studies to assess the appropriateness and feasibility of biologic substitution are still needed.

KW - Biologic therapy

KW - Certolizumab

KW - Crohn's Disease

UR - http://www.scopus.com/inward/record.url?scp=85035780964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035780964&partnerID=8YFLogxK

U2 - 10.1016/j.pathophys.2017.07.004

DO - 10.1016/j.pathophys.2017.07.004

M3 - Article

C2 - 28818362

AN - SCOPUS:85035780964

VL - 24

SP - 291

EP - 295

JO - Pathophysiology

JF - Pathophysiology

SN - 0928-4680

IS - 4

ER -